Gastroenterology Division, St. Luke's International University.
General Internal Medicine Division, Juntendo University.
Eur J Gastroenterol Hepatol. 2021 Nov 1;33(11):1341-1347. doi: 10.1097/MEG.0000000000002259.
Long-term cumulative incidence of and risk factors for metachronous advanced colorectal neoplasia, including both advanced colorectal adenoma (≥10 mm, or with villous or high-grade dysplasia) and colorectal cancer, are critical for surveillance strategies. The aim of this study was to determine the cumulative incidence of metachronous advanced colorectal neoplasia and its risk factors.
A retrospective cohort study was conducted on 6720 consecutive individuals who underwent general health check-ups and colonoscopy. Colorectal adenomas at initial colonoscopy were categorized as low-risk (1-2 small [<10 mm] tubular adenomas) or high-risk adenoma (≥3 tubular adenomas of any size; at least one adenoma ≥10 mm; or villous adenoma or adenoma with high-grade dysplasia). Kaplan-Meier estimates and hazard ratio by Cox-proportional hazard regression were calculated.
The cumulative incidence (95% confidence interval [CI]) of metachronous advanced colorectal neoplasia at 5 and 10 years was 5.7% [4.6-7.1], and 11% [8.9-14] in the low-risk adenoma group, and 10% [8.6-13], and 17% [14-21] in high-risk adenoma group, respectively. Adjusted hazard ratio [95% CI] of low-risk adenoma (vs. no colorectal adenoma), high-risk adenoma (vs. no colorectal adenoma), current smoking and positive fecal immunochemical test were 1.34 [1.04-1.74], 1.94 [1.48-2.55], 1.55 [1.2-2.02] and 1.69 [1.35-2.1], respectively. Adjusted hazard ratio [95% CI] of positive fecal immunochemical test was 1.88 [1.29-2.74] in those with normal colonoscopy.
Both low-risk and high-risk adenomas confer substantial risk for metachronous advanced colorectal neoplasia at 10 years. Positive fecal immunochemical test was a significant risk factor for metachronous advanced colorectal neoplasia despite normal colonoscopy.
对于结直肠腺瘤(≥10mm,或绒毛状或高级别异型增生)和结直肠癌在内的异时性晚期结直肠肿瘤的长期累积发生率和危险因素至关重要,这对于监测策略具有重要意义。本研究旨在确定异时性晚期结直肠肿瘤的累积发生率及其危险因素。
对 6720 例连续进行常规健康检查和结肠镜检查的个体进行回顾性队列研究。初始结肠镜检查时的结直肠腺瘤分为低危(1-2 个小腺瘤[<10mm])或高危腺瘤(任何大小≥3 个管状腺瘤;至少一个腺瘤≥10mm;或绒毛状腺瘤或高级别异型增生的腺瘤)。采用 Kaplan-Meier 估计和 Cox 比例风险回归计算风险比。
低危腺瘤组 5 年和 10 年异时性晚期结直肠肿瘤的累积发生率(95%置信区间[CI])分别为 5.7%(4.6-7.1)和 11%(8.9-14),高危腺瘤组分别为 10%(8.6-13)和 17%(14-21)。低危腺瘤(与无结直肠腺瘤相比)、高危腺瘤(与无结直肠腺瘤相比)、当前吸烟和粪便免疫化学检测阳性的调整后风险比(95%CI)分别为 1.34(1.04-1.74)、1.94(1.48-2.55)、1.55(1.2-2.02)和 1.69(1.35-2.1)。粪便免疫化学检测阳性在结肠镜检查正常的患者中发生异时性晚期结直肠肿瘤的调整后风险比为 1.88(1.29-2.74)。
低危和高危腺瘤在 10 年内发生异时性晚期结直肠肿瘤的风险均较大。尽管结肠镜检查正常,但粪便免疫化学检测阳性仍是异时性晚期结直肠肿瘤的重要危险因素。